Contents

ARTICLES

1423 Overlapping Drug Interaction Sites of Human Butyrylcholinesterase Dissected by Site-Directed Mutagenesis
Yael Loewenstein-Lichtenstein, David Glick, Nelly Gluzman, Meira Sternfeld, Haim Zakut, and Hermona Soreq

1432 Analysis of the α2C-Adrenergic Receptor Gene Promoter and Its Cell-Type-Specific Activity
Jean Sébastien Saulnier-Blache, Qing Yang, John D. Sherlock, and Stephen M. Lanier

1443 Activation of the Skeletal Muscle Ryanodine Receptor by Suramin and Suramin Analogs
Martin Hohenegger, Marina Matyash, Kati Poussu, Annegret Herrmann-Frank, Sandor Sarközi, Frank Lehmann-Horn, and Michael Freissmuth

1454 Basis for the Loss of Aryl Hydrocarbon Receptor Gene Expression in Clones of a Mouse Hepatoma Cell Line
Jianzhong Zhang, A. John Watson, Markus R. Probst, Elaine Minehart, and Oliver Hankinson

1463 Drug Sensitivity and Sequence Specificity of Human Recombinant DNA Topoisomerases IIα (p170) and IIβ (p180)
Mariagrazia Cornarotti, Stella Tinelli, Elaine Willmore, Franco Zunino, L. Mark Fisher, Caroline A. Austin, and Giovanni Caprano

1472 Acquired Camptothecin Resistance of Human Breast Cancer MCF-7/C4 Cells with Normal Topoisomerase I and Elevated DNA Repair
Akira Fujimori, Malini Gupta, Yuko Hoki, and Yves Pommier

Continued
CONTENTS (cont’d)

1479  Inverse Agonist-Induced Up-Regulation of the Human $\beta_2$-Adrenoceptor in Transfected Neuroblastoma X Glioma Hybrid Cells  David J. MacEwan and Graeme Milligan

1487  Enhanced Biological Activity of Antisense Oligonucleotides Complexed with Glycosylated Poly-L-lysine  A. J. Stewart, C. Pichon, L. Meunier, P. Midoux, M. Monsigny, and A. C. Roche

1495  Inhibition of Capacitative $\text{Ca}^{2+}$ Entry into Cells by Farnesylcysteine Analogs  Yajun Xu, Bryant A. Gilbert, Robert R. Rando, Longchuan Chen, and Armen H. Tashjian, Jr.

1502  Identification of Enzymes Catalyzing Two-Step Phosphorylation of Cidofovir and the Effect of Cytomegalovirus Infection on Their Activities in Host Cells  Tomas Cihlar and Ming S. Chen

1511  Transgenic Mice with High Levels of Superoxide Dismutase Activity are Protected from the Neurotoxic Effects of 2'-$\text{NH}_2$-MPTP on Serotonergic and Noradrenergic Nerve Terminals  Anne M. Andrews, Bruce Ladenheim, Charles J. Epstein, Jean Lud Cadet, and Dennis L. Murphy

1520  Effects of Volatile Anesthetics on the G Protein-Regulated Muscarinic Potassium Channel  Janos Magyar and Gabor Szabo

1529  Transport of Adenosine by Recombinant Purine-and Pyrimidine-Selective Sodium/Nucleoside Cotransporters from Rat Jejunum Expressed in Xenopus laevis Oocytes  Sylvia Y. M. Yao, Amy M. L. Ng, Mabel W. L. Ritzel, Wendy P. Gati, Carol E. Cass, and James D. Young


1541  Subtype-Selective Inhibition of N-Methyl-D-aspartate Receptors by Haloperidol  V. I. Ilyin, E. R. Whittemore, J. Guastella, E. Weber, and R. M. Woodward


1567  Alniditan, a New 5-Hydroxytryptamine$_{1\text{D}}$ Agonist and Migraine-Abortive Agent: Ligand-Binding Properties of Human 5-Hydroxytryptamine$_{1\text{Da}}$, Human 5-Hydroxytryptamine$_{1\text{DB}}$, and Calf 5-Hydroxytryptamine$_{1\text{D}}$ Receptors Investigated with $[^3\text{H}]$5-Hydroxytryptamine and $[^3\text{H}]$Alniditan  José E. Leysen, Walter Gommeren, Lieve Heylen, Walter H. M. L. Luyten, Inez Van De Weyer, Peter Vanhovenacker, Guy Haegeman, Alain Schotte, Paul Van Gompel, Ria Wouters, and Anne S. Lesage

Continued
CONTENTS (cont'd)

1581  Enantioselectivity of Steroid-Induced γ-Aminobutyric Acid<sub>A</sub> Receptor Modulation and Anesthesia

1587  Reconstitution of Recombinant Bovine A<sub>1</sub> Adenosine Receptors in Sf9 Cell Membranes with Recombinant G Proteins of Defined Composition

1596  Properties of the Pituitary Adenylate Cyclase-Activating Polypeptide I and II Receptors, Vasoactive Intestinal Peptide<sub>1</sub>, and Chimeric Amino-Terminal Pituitary Adenylate Cyclase-Activating Polypeptide/Vasoactive Intestinal Peptide<sub>1</sub> Receptors: Evidence for Multiple Receptor States

1605  Relative Contribution of Polar Interactions and Conformational Compatibility to the Binding of Neurokinin-1 Receptor Binding Antagonist

1612  Acid-Catalyzed Oxidation of the Anticancer Agent Mitoxantrone by Nitrite Ions

1619  The Third Extracellular Loop of the Human δ-Opioid Receptor Determines the Selectivity of δ-Opioid Agonists

1625  Evidence for an Internal Phenylalkylamine Action on the Voltage-Gated Potassium Channel Kv1.3

1635  Site-Directed Mutagenesis of the Human A<sub>1</sub> Adenosine Receptor: Influences of Acidic and Hydroxy Residues in the First Four Transmembrane Domains on Ligand Binding

1643  The Role of Inactivation in Open-Channel Block of the Sodium Channel: Studies with Inactivation-Deficient Mutant Channels

1651  Inverse Agonistic Effect of ICI-174,864 on the Cloned δ-Opioid Receptor: Role of G Protein and Adenylyl Cyclase Activation

Lisa L. Wittmer, Yuefei Hu, Melissa Kalkbrenner, Alex S. Evers, Charles F. Zorumski, and Douglas F. Covey

Robert A. Figler, Stephen G. Graber, Margaret A. Lindorfer, Hiroshi Yasuda, Joel Linden, and James C. Garrison

Jean Van Rampelbergh, Philippe Gourlet, Philippe De Neef, Patrick Robberecht, and Magali Waelbroeck

Tung Ming Fong, Hong Yu, Ruey-Ruey C. Huang, Margaret A. Cascieri, and Christopher J. Swain

Krzysztof J. Reszka and Colin F. Chignell


Heiko Rauer and Stephan Grissmer

Hemang Barbhaiya, Rebecca McClain, Adriaan IJzerman, and Scott A. Rivkees

Augustus O. Grant, J. Edward John, Vladislav V. Nesterenko, C. Frank Starmer, and J. Randall Moorman

Tillie T. Chiu, Lisa Y. Yung, and Yung H. Wong

Continued
<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>1665</td>
<td>Evans Blue Antagonizes Both α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionate and Kainate Receptors and Modulates Receptor Desensitization</td>
<td>Christopher J. Price and Lynn A. Raymond</td>
</tr>
<tr>
<td></td>
<td><strong>ACCELERATED COMMUNICATIONS</strong></td>
<td></td>
</tr>
<tr>
<td>1672</td>
<td>Novel Nonpeptide Agents Potently Block the C-Type Inactivated Conformation of Kv1.3 and Suppress T Cell Activation</td>
<td>Angela Nguyen, John C. Kath, Douglas C. Hanson, Michael S. Biggers, Paul C. Canniff, Carol B. Donovan, Robert J. Mather, Mathew J. Bruns, Heiko Rauer, Jayashree Aiyar, Albrecht Lepple-Wienhues, George A. Gutman, Stephan Grissmer, Michael D. Cahalan, and K. George Chandy</td>
</tr>
<tr>
<td>1680</td>
<td>Calcium-Dependent Inactivation of Recombinant N-Methyl-d-Aspartate receptors Is NR2 Subunit Specific</td>
<td>Johannes J. Krupp, Bryce Vissel, Stephen F. Heinemann, and Gary L. Westbrook</td>
</tr>
<tr>
<td>1689</td>
<td>Author Index to Volume 50</td>
<td></td>
</tr>
<tr>
<td>1700</td>
<td>Subject Index to Volume 50</td>
<td></td>
</tr>
</tbody>
</table>


*About the cover: Targeting of δ-opioid receptor to surface membranes. COS-1 cells were transfected with a mouse δ-opioid receptor mutant (D128A), for which the conserved aspartate in the third membrane domain is replaced by alanine. Cells were double-labeled with fluorescein-conjugated concanavalin A to label the plasma membrane (green) and with an anti-δ-opioid receptor antibody followed by rhodamine-conjugated streptavidin (red). Yellow shows the region of colocalization. This mutant exhibited reduced expression and subtle changes in its ability to bind certain agonist ligands. From Befort, K., L. Tabbara, S. Bausch, C. Chavkin, C. Evans, and B. Kieffer. The conserved aspartate residue in the third putative transmembrane domain of the δ-opioid receptor is not the anionic counterpart for cationic opiate binding but is a constituent of the receptor binding site. Mol. Pharmacol. 49: 216–223 (1996).*